Document is current
Any future updates will be listed below
-
Authors
Lu, Zhe
Stencel, Olivia
Liu, Wei
Vasileiou, Eleni https://orcid.org/0000-0003-4064-8744
Xu, Haifeng C
Pandey, Piyush
Stachura, Paweł https://orcid.org/0009-0005-4322-106X
Elwy, Abdelrahman
Tsombal, Anastassia
Mai, Ann-Sophie
Auer, Franziska
Morcos, Mina N F https://orcid.org/0000-0001-5812-9526
Seidl, Maximilian
Koziel, Sarah https://orcid.org/0009-0003-8002-5127
Bruch, Peter-Martin
Dietrich, Sascha
Elitzur, Sarah https://orcid.org/0000-0002-3495-7578
Hartmann, Gunther
Lang, Karl S
Janssen, Stefan
Fischer, Ute https://orcid.org/0000-0002-2455-2489
Bhatia, Sanil https://orcid.org/0000-0001-6494-7744
Lang, Philipp A
Borkhardt, Arndt https://orcid.org/0000-0002-6121-4737
Hauer, Julia https://orcid.org/0000-0002-4058-3058
Pandyra, Aleksandra A https://orcid.org/0000-0003-4794-0035
-
Funding
Funding for this research was provided by:
José Carreras Leukämie-Stiftung (18R/2021,07/19)
Bundesamt für Strahlenschutz
Deutsches Zentrum für Infektionsforschung (TTU 07-711)
Deutsches Zentrum für Infektionsforschung (TTU 07.834)
Deutsche Forschungsgemeinschaft (495318549)
Deutsche Forschungsgemeinschaft (547295412)
Deutsche Forschungsgemeinschaft (EXC2151-390873048;DFG TRR237; DFG TRR259)
Deutsche Forschungsgemeinschaft (LA2558/8-1,RTG1949)
EC | European Research Council (85222)
China Scholarship Council
Christiane und Claudia Hempel Stiftung
Bundesministerium für Bildung und Forschung (01KD2410A (EDI-4-ALL))
Bundesministerium für Bildung und Forschung (01KT2311;01KU2210)
Katharina-Hardt Stiftung (3618S32275; 3618S32275)
Loewenstern
Deutsche Krebshilfe (70114539)
Deutsche Krebshilfe (Priority Program Cancer Prevention-Graduate School)
Duesseldorf School of Oncology
Deutsche Kinderkrebsstiftung (A2023/31)
Hairy Cell Leukemia Foundation
Else Kroener Fresenius Foundation
Young Investigator Grant of the Medical Faculty Düsseldorf
Jurgen Manchot Foundation
Volkswagen Foundation
Medical Faculty of the Heinrich Heine University
- License Information
-
More Information
Article History
Received: 31 May 2024
Revised: 19 February 2025
Accepted: 20 February 2025
First Online: 13 March 2025
Disclosure and competing interests statement
: PAL, KSL, HCX, and PP declare that they are involved in the development of LCMV for clinical application in oncology in cooperation with, as founders of, or as advisors to Abalos Therapeutics GmbH. The remaining authors declare no competing interests.
